<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5077">
  <stage>Registered</stage>
  <submitdate>1/12/2014</submitdate>
  <approvaldate>1/12/2014</approvaldate>
  <nctid>NCT02316886</nctid>
  <trial_identification>
    <studytitle>The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Vulnerable Plaque</studytitle>
    <scientifictitle>The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics</scientifictitle>
    <utrn />
    <trialacronym>PREVENT</trialacronym>
    <secondaryid>AMCCV2014-13</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <healthcondition>Plaque, Atherosclerotic</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Coronary intervention
Treatment: drugs - Optimal Medical treatment

Experimental: Coronary intervention - Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment

Active Comparator: Optimal Medical Treatment - Optimal Medical Treatment


Treatment: devices: Coronary intervention
Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment

Treatment: drugs: Optimal Medical treatment


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>cardiovascular death</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Nonfatal myocardial infarction</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Ischemia driven target lesion revascularization</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Major adverse cardiac event - defined as cardiovascular death, nonfatal myocardial infarction, or unplanned rehospitalization due to unstable angina</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target vessel failure, defined as a composite of cardiovascular death, target vessel related myocardial infarction, or target vessel revascularization - The composite of death, MI, and any TVR at a mean of 2 years follow-up.</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death from any causes</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The composite of death, myocardial infarction, and any repeat revascularization - The composite of death, myocardial infarction, and any repeat revascularization at a mean of 2 years follow-up.</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac death and combinations of cardiac death with other components of MACE at each time point - Cardiac death and combinations of cardiac death with other components of MACE at each time point</outcome>
      <timepoint>1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac death and combinations of cardiac death with other components of MACE at each time point - Cardiac death and combinations of cardiac death with other components of MACE at each time point</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac death and combinations of cardiac death with other components of MACE at each time point - Cardiac death and combinations of cardiac death with other components of MACE at each time point</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac death and combinations of cardiac death with other components of MACE at each time point - Cardiac death and combinations of cardiac death with other components of MACE at each time point</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non-urgent revascularization procedures</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CCS(Canadian Cardiovascular Society) angina class</outcome>
      <timepoint>1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CCS(Canadian Cardiovascular Society) angina class</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CCS(Canadian Cardiovascular Society) angina class</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CCS(Canadian Cardiovascular Society) angina class</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of anti-anginal medication at each point in time</outcome>
      <timepoint>1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of anti-anginal medication at each point in time</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of anti-anginal medication at each point in time</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of anti-anginal medication at each point in time</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of non-urgent (repeat) revascularization at each point in time</outcome>
      <timepoint>1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of non-urgent (repeat) revascularization at each point in time</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of non-urgent (repeat) revascularization at each point in time</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of non-urgent (repeat) revascularization at each point in time</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age 18 years or older

          -  Symptomatic or asymptomatic coronary artery disease patients

          -  Patients having at least one significant stenosis (diameter stenosis &gt; 50%) with FFR
             &gt;0.80 and meeting two of the following:

               1. MLA(minimal luminal area)&lt;4mm2

               2. plaque burden&gt;70%

               3. Lipid-rich plaque on NIRS(Intracoronary Near-Infrared Spectroscopy) (defined as
                  maxLCBI4mm&gt;315)

               4. TCFA(thin-cap fibroatheroma) defined by OCT(fibrous cap thickness&lt;65µm and
                  arc&gt;90°) or VH-IVUS=10% confluent NC with&gt;30° abutting to the lumen in 3
                  consecutive slices)

                    -  2 target vulnerable lesions

          -  Eligible for percutaneous coronary intervention with Absorb Bioresorbable Vascular
             Scaffold or Everolimus Eluting Stent

          -  Willing and able to provide informed written consent

          -  Reference vessel diameter 2.75-4.0

          -  Lesion length = 40</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients in whom the preferred treatment is CABG(Coronary artery bypass grafting)

          -  Stented lesion

          -  Bypass graft lesion

          -  The patients who have more than or equal to 3 target lesions

          -  2 target lesions in the same coronary territory

          -  Heavily calcified or angulated lesion

          -  Bifurcation lesion requiring 2 stenting technique

          -  Contraindication to or planned discontinuation of dual antiplatelet therapy within 1
             year

          -  Life expectancy less than 2 years

          -  Planned cardiac surgery or planned major non cardiac surgery

          -  Woman who are breastfeeding, pregnant or planning to become pregnant during the course
             of the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Northern Hospital , Victoria Australia - Epping</hospital>
    <hospital>Eastern Heart Clinic, Prince of Wales Hospital - Randwick</hospital>
    <postcode> - Epping</postcode>
    <postcode> - Randwick</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kurashiki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Wakayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Songpa-gu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Anyang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Chuncheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Dae-jeon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daejeon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gwangju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jeonju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Pusan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Sungnam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Ulsan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Seung-Jung Park</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>CardioVascular Research Foundation, Korea</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether preventive coronary intervention on
      functionally insignificant coronary stenosis with vulnerable plaque characteristics plus
      optimal medical therapy reduces the incidence of the composite of cardiovascular death,
      target vessel myocardial infarction, or ischemia driven target lesion revascularization
      compared with optimal medical therapy alone.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02316886</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregg Stone, MD</name>
      <address>Columbia University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Jung-Min Ahn, MD</name>
      <address />
      <phone />
      <fax />
      <email>drjmahn@gmail.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>